Spinal Muscle Atrophy Clinical Presentation
- Author: Jose A Herrera-Soto, MD; Chief Editor: Mary Ann E Keenan, MD more...
History
- Type I: Most mothers report abnormal inactivity of the fetus in the latter stages of pregnancy. The patient with type I spinal muscle atrophy (spinal muscular atrophy, SMA) is unable to roll over or sit. Progressive clinical deterioration occurs. Death usually occurs from respiratory failure and its complications in patients by age 2 years.
- Type II: Patients with type II SMA have normal development for the first 4-6 months of life. They may be able to sit independently, but they are never able to walk. They require a wheelchair for locomotion. They have a longer life span than patients with type I SMA. Some patients with type II SMA live into the fifth decade of life.
- Type III: In patients with type III SMA, the presenting complaint is difficulty climbing stairs or getting up from the floor (due to hip extensor weakness). The life span is nearly normal.[15]
Physical
- Physical findings specific for each type of spinal muscle atrophy (spinal muscular atrophy, SMA) are as follows:
- Type I: Newborns with type I SMA are floppy and inactive. They move the extremities little, if at all. The hips are flexed, abducted, and externally rotated. The knees are flexed. Because the distal musculature is usually spared, the fingers and toes move. Infants cannot control or lift the head. Areflexia is universal.
- Type II: Patients with type II SMA have head control, and 75% of these patients can sit independently. Muscular weakness is greater in the lower extremities than the upper extremities. Patellar reflex is absent. The young may demonstrate bicipital and triceps tendon reflexes. Tongue fasciculations are present, as are upper extremity tremors. Scoliosis is universal, and most patients develop hip dislocation, either unilateral or bilateral, when younger than 10 years.
- Type III: These patients walk early in life and maintain their ambulatory capacity into adolescence. Weakness may cause foot drop, and patients have limited endurance. A third of the patients become wheelchair bound as adults (mean age 40 years).
- Other physical findings associated with SMA are as follows:
- A long C-shaped thoracolumbar scoliotic curve is present in patients with type II SMA and in half of patients with type III SMA. The curve progresses to a severe and incapacitating deformity if not treated. Thirty percent of patients have kyphotic deformities as well.
- Pseudohypertrophy of the calf is present, which may confound the diagnosis (ie, with Duchenne muscular dystrophy and Becker muscular dystrophy). Bouwsma reported that this finding was associated with elevated serum creatine kinase (CK).[16] This combination was only observed in males; no females in his series had hypertrophy of the calves.[16]
- Tongue fasciculations are pathognomonic of SMA (all types), as opposed to all other neuromuscular diseases of infancy. Presence of tongue fasciculations can aid in the diagnosis, as 56% of patients exhibit this symptom.
Causes
Patients with spinal muscle atrophy (spinal muscular atrophy, SMA) have a homozygous deletion of the telomeric SMN1 (survival motor neuron) gene found in arm 5q (bands q11.2-13.3).[9] This deletion has been demonstrated in up to 98% of patients with SMA. SMN is part of a multiprotein complex required for the biogenesis of small nuclear ribonucleoproteins.[17, 18]SMN1 has been linked to pre-mRNA splicing, spliceosome biogenesis, and the nucleolar protein fibrillarin. The absence or dysfunction of SMN is reflected by an enhanced neuronal death. A heterozygous deletion leads to an asymptomatic carrier state.[19]
A significant increase in nuclear DNA vulnerability was detected in fetuses with SMA at 12-15 weeks' gestational age. It reflected a decrease in the number of anterior horn neurons. This vulnerability is no longer seen in the rest of the prenatal or postnatal period. Abnormal cell morphology was seen only in the postnatal period.[20]
Aiona MD, Sarwark JF, Sussman MD. Neuromuscular disorders in children. In: Orthopaedic Knowledge Update. American Academy of Orthopaedic Surgeons;1999:240-241.
Bowen JR, Forlin E. Spinal muscular atrophy. In: Weinstein SL, ed. The Pediatric Spine: Principles and Practice. New York, NY: Raven Press; 1994:1025-1042.
Cifuentes-Diaz C, Frugier T, Melki J. Spinal muscular atrophy. Semin Pediatr Neurol. Jun 2002;9(2):145-50. [Medline].
Herring JA. Disorders of the spinal cord. In: Tachdjian Pediatric Orthopaedics. vol 2. Philadelphia, Pa: WB Saunders Co; 2002:1311-1319.
Werdnig G. Ueber einem Fall von Dystrophiae musculorum mit positivenen Ruckenmakefunde. Wien me Wchnschr. 1890;40:1798.
Kugelberg E, Welander L. Heredo-familial juvenile muscular atrophy simulating muscular dystrophy. AMA Arch Neurol Psychiatry. 1956;75:500.
Hoffman J. Ueber chronische spinale Muskelatophie im Kindersalter. Deutsch Ztschv f Nerrenh. 1891;1:95.
Soler-Botija C, Ferrer I, Gich I, et al. Neuronal death is enhanced and begins during foetal development in type I spinal muscular atrophy spinal cord. Brain. Jul 2002;125(Pt 7):1624-34. [Medline].
Brzustowicz LM, Lehner T, Castilla LH, et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature. Apr 5 1990;344(6266):540-1. [Medline].
Pearn J. Genetic studies of acute infantile spinal muscular atrophy (SMA type I). An analysis of sex ratios, segregation ratios, and sex influence. J Med Genet. Dec 1978;15(6):414-7. [Medline].
Burd L, Short SK, Martsolf JT, Nelson RA. Prevalence of type I spinal muscular atrophy in North Dakota. Am J Med Genet. Nov 1 1991;41(2):212-5. [Medline].
Simic G. Pathogenesis of proximal autosomal recessive spinal muscular atrophy. Acta Neuropathol. Jul 16 2008;[Medline].
Thieme A, Mitulla B, Schulze F, Spiegler AW. Epidemiological data on Werdnig-Hoffmann disease in Germany (West- Thuringen). Hum Genet. Apr 1993;91(3):295-7. [Medline].
Hausmanowa-Petrusewicz I, Zaremba J, Borkowska J. Chronic proximal spinal muscular atrophy of childhood and adolescence: sex influence. J Med Genet. Dec 1984;21(6):447-50. [Medline].
Piepers S, van den Berg LH, Brugman F, Scheffer H, Ruiterkamp-Versteeg M, van Engelen BG, et al. A natural history study of late onset spinal muscular atrophy types 3b and 4. J Neurol. Jun 30 2008;[Medline].
Bouwsma G, Van Wijngaarden GK. Spinal muscular atrophy and hypertrophy of the calves. J Neurol Sci. Jan 1980;44(2-3):275-9. [Medline].
Narayanan U, Ospina JK, Frey MR, et al. SMN, the spinal muscular atrophy protein, forms a pre-import snRNP complex with snurportin1 and importin beta. Hum Mol Genet. Jul 15 2002;11(15):1785-95. [Medline].
Wehner KA, Ayala L, Kim Y, et al. Survival motor neuron protein in the nucleolus of mammalian neurons. Brain Res. Aug 2 2002;945(2):160-73. [Medline].
Thi Man N, Humphrey E, Lam LT, Fuller HR, Lynch TA, Sewry CA, et al. A two-site ELISA can quantify upregulation of SMN protein by drugs for spinal muscular atrophy. Neurology. Jul 16 2008;[Medline].
Panigrahi I, Kesari A, Phadke SR, Mittal B. Clinical and molecular diagnosis of spinal muscular atrophy. Neurol India. Jun 2002;50(2):117-22. [Medline].
Rudnik-Schöneborn S, Heller R, Berg C, Betzler C, Grimm T, Eggermann T, et al. Congenital heart disease is a feature of severe infantile spinal muscular atrophy. J Med Genet. Jul 28 2008;[Medline].
Little SE, Janakiraman V, Kaimal A, Musci T, Ecker J, Caughey AB. The cost-effectiveness of prenatal screening for spinal muscular atrophy. Am J Obstet Gynecol. Mar 2010;202(3):253.e1-7. [Medline].
Pandey R, Chandratre S, Roberts A, Dwyer JS, Sewry C, Quinlivan R. Central core myopathy with RYR1 mutation masks 5q Spinal Muscular Atrophy. Eur J Paediatr Neurol. May 7 2010;[Medline].
Stavarachi M, Apostol P, Toma M, Cimponeriu D, Gavrila L. Spinal muscular atrophy disease: a literature review for therapeutic strategies. J Med Life. Jan-Mar 2010;3(1):3-9. [Medline].
Lorson CL, Rindt H, Shababi M. Spinal muscular atrophy: mechanisms and therapeutic strategies. Hum Mol Genet. Apr 15 2010;19:R111-8. [Medline]. [Full Text].
Han JJ, McDonald CM. Diagnosis and clinical management of spinal muscular atrophy. Phys Med Rehabil Clin N Am. Aug 2008;19(3):661-80. [Medline].
Schwentker EP, Gibson DA. The orthopaedic aspects of spinal muscular atrophy. J Bone Joint Surg Am. Jan 1976;58(1):32-8. [Medline].
Shapiro F, Specht L. The diagnosis and orthopaedic treatment of childhood spinal muscular atrophy, peripheral neuropathy, Friedreich ataxia, and arthrogryposis. J Bone Joint Surg Am. Nov 1993;75(11):1699-714. [Medline].
Narver HL, Kong L, Burnett BG, Choe DW, Bosch-Marcé M, Taye AA, et al. Sustained improvement of spinal muscular atrophy mice treated with trichostatin a plus nutrition. Ann Neurol. Jul 25 2008;[Medline].
Takeuchi Y, Katsuno M, Banno H, Suzuki K, Kawashima M, Atsuta N, et al. Walking capacity evaluated by the 6-minute walk test in spinal and bulbar muscular atrophy. Muscle Nerve. Jul 18 2008;38(2):964-971. [Medline].
Aagaard P, Suetta C, Caserotti P, Magnusson SP, Kjaer M. Role of the nervous system in sarcopenia and muscle atrophy with aging: strength training as a countermeasure. Scand J Med Sci Sports. Feb 2010;20(1):49-64. [Medline].
Zeesman S, Whelan DT, Carson N, et al. Parents of children with spinal muscular atrophy are not obligate carriers: carrier testing is important for reproductive decision-making. Am J Med Genet. Jan 22 2002;107(3):247-9. [Medline].

